Varex Imaging Corp (VREX) — Titan Protect Analysis

VREX

Varex Imaging Corp

Healthcare · ·

$10.09

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$416M

Total market value of the company

Trailing P/E

N/A

Forward P/E

9.25

Based on estimated future earnings — lower means cheaper

Rev Growth

+1.5%

Year-over-year revenue change

Profit Margin

-9.6%

How much profit the company keeps from each dollar of revenue

ROE

-15.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$18.00

+78% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 5 analysts covering this stock

About Varex Imaging Corp

Varex Imaging Corporation designs, manufactures, and sells X-ray imaging components. It operates through two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components, comprising X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, genera

https://www.vareximaging.com

Country: United States Employees: 2,450 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.071

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0339

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.321

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-18.9%

Historical annualised return based on price data

Max Drawdown

-58.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.96

Less volatile than the market — more defensive

52W High

$14.57

31% below the year high

52W Low

$6.76

49% above the year low

Avg Volume

357,288

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.00

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

78.06

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

33.6%

Revenue left after cost of goods — higher means pricing power

Operating Margin

6.7%

Profit from core operations before interest and tax

Free Cash Flow

$-40,275,000

Negative — the business is spending more than it generates

Revenue (TTM)

$858M

Total revenue over the last 12 months

Net Income

$-82,700,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$22.00

Target Median

$18.00

Target Low

$16.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go